Dabigatran: high cost burden if no prescription drug coverage
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2015 Category: Drugs & Pharmacology Source Type: news
Oct 30 Cardiology NewsOct 30 Cardiology News
Dabigatran in women, advance practice practitioners in cardiology, burst exercise for type 2 diabetes, cannabis and ischemic stroke, and Science of the Art of Medicine are reviewed by Dr Mandrola. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 30, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Stroke Rounds: Gender Difference Seen in Dabigatran Dosing (CME/CE)
(MedPage Today) -- In Canada, women tend to receive intermediate dosage not available in the U.S. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 29, 2015 Category: Cardiology Source Type: news
Dabigatran Use, Effectiveness Differs for Women vs Men With AFDabigatran Use, Effectiveness Differs for Women vs Men With AF
"At least in Canada, we're saying that the 150-mg dose should be prescribed as much as possible in women because it offers better protection for stroke prevention with similar bleeding risk," the PI said. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 28, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Oct 23 Cardiology NewsOct 23 Cardiology News
Treating patients with severe asymptomatic aortic stenosis, dabigatran reversal, valve-in-valve TAVR, and an oral potassium binder are the topics for this week's podcast from Dr John Mandrola theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 23, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
FDA Approves Boehringer's Pradaxa Reversal Drug
The U.S. FDA granted accelerated approval to Boehringer Ingelheim's Praxbind for use in patients who are taking the anticoagulant Pradaxa during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 20, 2015 Category: Pharmaceuticals Source Type: news
Dabigatran-Reversal Agent Price Set (FREE)
By Joe Elia
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Idarucizumab (Praxbind), an agent … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 20, 2015 Category: Primary Care Source Type: news
FDA Approves First Dabigatran Reversal Agent (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
The FDA on Friday granted accelerated approval for idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa) in emergency situations. Idarucizumab, an injectable monoclonal antibody fragment, binds to dabigatran and thereby neutralizes its effect.Approval was based on three trials … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 19, 2015 Category: Primary Care Source Type: news
Boehringer's Praxbind gets FDA approval as specific reversal agent for Pradaxa
Boehringer Ingelheim Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Praxbind (idarucizumab) as a specific reversal agent for Pradaxa (dabigatran etexilate mesylate). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 18, 2015 Category: Pharmaceuticals Source Type: news
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
- For Media outside of the US (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 18, 2015 Category: Research Source Type: news
Dabigatran Reversal Drug Holds Promise (CME/CE)
(MedPage Today) -- Preliminary research suggests idarucizumab can reverse anticoagulant's bleeding risk (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 17, 2015 Category: Cardiology Source Type: news
FDA OKs Drug to Reverse Blood Thinner's Effect
Praxbind cleared for emergency use with Pradaxa when bleeding can't be controlled (Source: WebMD Health)
Source: WebMD Health - October 17, 2015 Category: Consumer Health News Source Type: news
FDA Approves Praxbind to Reverse Anticoagulant PradaxaFDA Approves Praxbind to Reverse Anticoagulant Pradaxa
The FDA has approved Praxbind, a drug designed to rapidly reverse the anticoagulant effects of Pradaxa. FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 17, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Drug to Reverse Blood Thinner's Effect
Praxbind cleared for emergency use with Pradaxa when bleeding can't be controlled
Source: HealthDay
Related MedlinePlus Pages: Blood Thinners, Drug Safety (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 16, 2015 Category: Consumer Health News Source Type: news
FDA approves Boehringer's blood thinner reversal agent
(Reuters) - U.S. health regulators on Friday approved Praxbind, a reversal agent made by Germany's privately held Boehringer Ingelheim, for use in emergency situations by patients taking the company's widely used Pradaxa blood thinner. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
